Data of Viral Respiratory Diseases on Sorok Island during the Pandemic
Our study found a specific NLRP3 competitor (4,4′-diaminodiphenyl sulfone, DDS) for COVID-19 ARDS treatment. It combines clinical, theoretical, and statistical analyses of chemical and pharmaceutical knowledge of the interaction between the Dapsone and NLRP3. In addition, SARS-CoV-2 works as the inflammasome in the mesoscopic area. They might be originated from T-cell activation caused by HLA polymorphism. It has been tentatively concluded that the Pandemic virus might act to induce inflammasome.
Steps to reproduce
Identification of safe, effective treatment for individuals with mild or moderate COVID-19 acute respiratory distress syndrome (ARDS) that prevents disease progression would reduce mortality.